SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > p38 MAPK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.